Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05690841
Other study ID # 22-36417
Secondary ID 1U01AI15796223-0
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date June 1, 2024
Est. completion date May 1, 2027

Study information

Verified date February 2024
Source University of California, San Francisco
Contact Sydney Fine, MPH
Phone 415-476-5494
Email sydney.fine@ucsf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru. Standard interventions, including symptomatic and asymptomatic screening for malaria infections, provision of insecticide-treated bednets, and environmental transmission monitoring, will be compared to clusters of villages randomized to receive anti-malarial drugs.


Description:

This trial trial is an open-label cluster-randomized controlled trial in Loreto Region, Peru, a low transmission setting (i.e. anual incidence <250/1000), where the unit of randomization is a village, or cluster. There will be two study arms: Control and fMDA. Villages will receive fMDA or control based on a restricted randomization that includes baseline factors such as incidence, distance to a health post, and population. The interventions for both control and fMDA clusters will include standard interventions (high coverage of vector control, passive and active symptomatic case management, and RACD of asymptomatic cases). The intervention will take place in 2 rounds two months apart for three cycles, each cycle separated by regular intervals of 9-11 months. fMDA will target high-risk villagers (individuals residing in households that are within 200 meters of a Pv index case households from the prior 2 years). High-risk status will be determined in each survey before the administration of Round "a" of fMDA. Pv index cases refers to confirmed Pv cases reported by the health system. In each cycle of fMDA, the 1st round will include 3 days of chloroquine (CQ) for treatment of Pv asexual blood stages, with TQ for Pv liver stages. With a prolonged half-life up to 15 days and post-treatment effect observed up to 77 days. TQ will also have a prophylactic and likely gametocytocidal effect for Pv and Pf. For continued anti-relapse, prophylactic, and transmission-blocking effects, a follow-up round (2 months after each 1st round) will include TQ with single-dose CQ (sdCQ). If TQ, but not PQ, is contraindicated, a standard 7-day PQ course will be used. CQ, including in a single dose, will potentiate the anti-relapse effect of PQ, and likely TQ. Preliminary data from the study area shows that 32% of the study population is <16 years old and will receive PQ. However, the investigators do not anticipate this to influence the impact of the fMDA due to our use of directly observed therapy (DOT). If pediatric TQ is approved for use in Peru during the study, an addendum to the protocol will be presented for approval by the IRB and INS and incorporated into the study. An end-line survey will be carried out at the end of the 3-year trial intervention period. Interim surveys will also be conducted in both arms. In each of these surveys, a blood sample will be collected in microtainer tubes, and a dried blood spot will be collected from anyone with fever in the prior 48 hours and a positive blood smear from a local health post. They will receive treatment per national policy. Anyone with fever in the prior 48 hours without a positive blood smear will be encouraged to go to a health post, but if not, study staff will collect a blood smear and they will receive treatment per national policy if found to have malaria. To maximize public health relevance, the trial will be pragmatic and implemented through the existing health system. The primary research objectives are: 1. To determine the effectiveness of three rounds of fMDA to reduce Pv transmission in the Loreto Department, Peru compared to standard interventions. 2. To evaluate the safety and tolerability of fMDA by measuring incidence of severe adverse events or severe malaria in the treatment arm. 3. To measure the cost-effectiveness and acceptability of fMDA by calculating the cost per malaria case averted for intervention and control arms.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 7700
Est. completion date May 1, 2027
Est. primary completion date May 1, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Cluster eligibility - Within 8 hours transport of Iquitos - Incidence <250/1000 and >2 cases year prior to trial - Population size (<650) 2. Chloroquine (CQ) eligibility - Resides in neighboring household but within 200 m of Pv index case in the past 2 years - Age =6 months old - Present for intervention - Adult =18 years old that provides informed consent - A child =8 years and <18 years old that provides informed assent and has informed consent from their parents - A child =6 months old and <8 years old that has informed consent from their parents 3. Tafenoquine (TQ) eligibility - Eligible to receive CQ - Age =16 years old - Adult =18 years old that provides informed consent - A child =16 years and <18 years old that provides informed assent and has informed consent from their parents 4. Primaquine eligibility - Eligible to receive CQ and ineligible to receive TQ - Age =6 months old - Adult =18 years old that provides informed consent - A child =8 years and <18 years old that provides informed assent and has informed consent from their parents - A child =6 months old and <8 years old that has informed consent from their parents 5. Baseline evaluation and informed consent -Villagers will be eligible to participate in surveys if they slept in a household in cluster randomized to control or focal mass drug administration (fMDA) for at least one night in the past four weeks 6. Eligibility for fMDA - High-risk villagers are defined as individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household) will be eligible to receive fMDA that cycle - Villagers that were eligible but missed in the 1st annual round, or become eligible in the next two months, can receive fMDA in the 2nd annual round. Exclusion Criteria: 1. Chloroquine eligibility - History of retinal or visual field changes - Known hypersensitivity or adverse reaction to CQ - Currently taking CQ or have taken CQ in the past four weeks - Ineligible for TQ or PQ (see criteria below) - Hemoglobin <7 g/dL 2. Tafenoquine eligibility - G6PD deficiency or intermediate status (defined as activity =6.0 UI/gHb per SD biosensor) - G6PD status unknown or refusal of G6PD status test - Acute or severe malaria - Pregnancy (known or identified by pregnancy test) - Refusal of pregnancy test if new amenorrhea in the past 4 weeks - Woman breastfeeding a child that is G6PD deficient or with unknown G6PD status - Known hypersensitivity or adverse reaction to TQ or PQ - Have taken mefloquine (i.e. artesunate- mefloquine), TQ or PQ, or other antimalarial in the past four weeks - Hemoglobin < 7 g/dL 3. Primaquine eligibility - G6PD deficiency (defined as activity =4.0 UI/gHb per SD biosensor) - G6PD status unknown or refusal of G6PD status test - Acute or severe malaria - Pregnancy (known or identified by pregnancy test) - Refusal of pregnancy test if new amenorrhea in the past 4 weeks - Breastfeeding child with documented or unknown G6PD deficiency status - Known hypersensitivity or adverse reaction to TQ or PQ - Have taken mefloquine (i.e. artesunate- mefloquine), TQ or PQ, or other antimalarial in the past four weeks - Hemoglobin < 7 g/dL

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Focal Mass Drug Administration (fMDA)
Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by 9-11 month intervals. Each year will include 2 rounds of fMDA. Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for >= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for <16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals >=6mo and <16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing). Round 2) single dose CQ+TQ for >= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for <16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals >=6mo and <16y ((CQ: Day1 600 mg, PQ age-based dosing).

Locations

Country Name City State
Peru Universidad Peruana de Cayetano Heredia Lima

Sponsors (7)

Lead Sponsor Collaborator
University of California, San Francisco Eijkman Oxford Clinical Research Unit, Indonesia, Menzies School of Health Research, National Institute of Allergy and Infectious Diseases (NIAID), PATH, Stanford University, Universidad Peruana Cayetano Heredia- subcontractor to UCSF as local Sponsor

Country where clinical trial is conducted

Peru, 

References & Publications (6)

Hsiang MS, Hwang J, Tao AR, Liu Y, Bennett A, Shanks GD, Cao J, Kachur SP, Feachem RG, Gosling RD, Gao Q. Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J. 2013 Nov 1;12:383. doi: 10.1186/1475-2875-12-383. — View Citation

Hsiang MS, Ntuku H, Roberts KW, Dufour MK, Whittemore B, Tambo M, McCreesh P, Medzihradsky OF, Prach LM, Siloka G, Siame N, Gueye CS, Schrubbe L, Wu L, Scott V, Tessema S, Greenhouse B, Erlank E, Koekemoer LL, Sturrock HJW, Mwilima A, Katokele S, Uusiku P, Bennett A, Smith JL, Kleinschmidt I, Mumbengegwi D, Gosling R. Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial. Lancet. 2020 Apr 25;395(10233):1361-1373. doi: 10.1016/S0140-6736(20)30470-0. — View Citation

Llanos-Cuentas A, Lacerda MVG, Hien TT, Velez ID, Namaik-Larp C, Chu CS, Villegas MF, Val F, Monteiro WM, Brito MAM, Costa MRF, Chuquiyauri R, Casapia M, Nguyen CH, Aruachan S, Papwijitsil R, Nosten FH, Bancone G, Angus B, Duparc S, Craig G, Rousell VM, Jones SW, Hardaker E, Clover DD, Kendall L, Mohamed K, Koh GCKW, Wilches VM, Breton JJ, Green JA. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med. 2019 Jan 17;380(3):229-241. doi: 10.1056/NEJMoa1802537. — View Citation

Ntuku H, Smith-Gueye C, Scott V, Njau J, Whittemore B, Zelman B, Tambo M, Prach LM, Wu L, Schrubbe L, Kang Dufour MS, Mwilima A, Uusiku P, Sturrock H, Bennett A, Smith J, Kleinschmidt I, Mumbengegwi D, Gosling R, Hsiang M. Cost and cost effectiveness of reactive case detection (RACD), reactive focal mass drug administration (rfMDA) and reactive focal vector control (RAVC) to reduce malaria in the low endemic setting of Namibia: an analysis alongside a 2x2 factorial design cluster randomised controlled trial. BMJ Open. 2022 Jun 23;12(6):e049050. doi: 10.1136/bmjopen-2021-049050. — View Citation

PAHO. Fourth Meeting of the Malaria Technical Advisory Group (TAG) to the Pan American Health Organization (PAHO). Washington D.C.: Pan American Health Organization, World Health Organization, Americas. https://www.paho.org/hq/index.php?option=com_docman&view=download&alias=50391-fourthmalaria-technical-advisory-group-meeting-report-may-washington-dc&category_slug=malariatechnical-advisory-group&Itemid=270&lang=en; 2019.

World Health Organization (WHO). WHO Guidelines for malaria. 3 June 2022. https://reliefweb.int/report/world/who-guidelines-malaria-3-june-2022#:~:text=The%20WHO%20global%20malaria%20strategy,residual%20foci%20of%20malaria%20transmission.

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative Incidence of Plasmodium vivax infections Number of microscopy-confirmed, Plasmodium vivax malaria cases in residents reported from health facilities per population over the 36-month follow-up study period From enrollment through study completion, over 36-month follow-up study period
Secondary Prevalence of Plasmodium vivax infection Proportion of individuals with polymerase chain reaction (PCR)-confirmed infection in an endline survey At endline survey in trial year 4, 3 years after enrollment in study in trial year 1
Secondary Plasmodium vivax seroprevalence Proportion of participants who are seropositive, rate at which seronegative individuals became seropositive estimated from age-specific seroprevalence from endline survey, adjusted by modeling longitudinal individual serological status and/or antibody titers At endline survey in trial year 4, 3 years after enrollment in study in trial year 1
Secondary Genetic diversity of Plasmodium vivax Diversity of locally acquired infections as defined by sequencing results From enrollment through study completion, over 4 trial years
Secondary Tolerability of study drugs Vomiting following administration of study drugs and non-adherence related to adverse effects Over drug administration period, unique for each study drug (7 days for CQ/PQ regimens and 3 days for CQ/TQ regimens)
Secondary Adherence to study drugs Number of missed doses Unique for each patient based on drug regimen (7 days for CQ/PQ regimens and 3 days for CQ/TQ regimens)
Secondary Refusal rates Number of refusals divided by number of individuals invited to participate During each fMDA round, twice per year for 3 consecutive years
Secondary Program costs per unit fMDA round Total costs divided by number of fMDA rounds From enrollment through study completion, over 4 years
Secondary Program costs per unit Total costs divided by number of individuals receiving intervention From enrollment through study completion, over 4 years
Secondary Cost per incident case averted Difference in cost between fMDA and control divided by the difference in the effect (incidence) From enrollment through study completion, over 4 years
Secondary Cost per disability life year (DALY) Difference in cost between fMDA and control divided by the difference in the effect (DALYs) From enrollment through study completion, over 4 years
Secondary Cost per economic dollar due to malaria saved Difference in cost between fMDA and control divided by the difference in the effect (economic dollar due to malaria) From enrollment through study completion, over 4 years
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed NCT02605720 - Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns Phase 3